SAFETY DATA SHEET
Cat# 1617-5, -50, Canertinib (CI-1033, PD-183805)          SDS DATE: Feb 29, 2012

SECTION 1: PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME: Canertinib (CI-1033, PD-183805)

PRODUCT CODES: Cat# 1617-5, -50

MANUFACTURER: BioVision, Inc.
ADDRESS: 155 S. Milpitas Boulevard, Milpitas, CA 95035

EMERGENCY PHONE: 858-373-8066
CHEMTREC PHONE: OTHER CALLS: 408-493-1800
FAX PHONE: 408-493-1801

SECTION 2: COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
<th>Volume</th>
<th>Safety Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canertinib (CI-1033, PD-183805)</td>
<td>Solid</td>
<td>1617-5: 5 mg 1617-50: 50 mg</td>
<td>See below</td>
</tr>
</tbody>
</table>

SECTION 3: HAZARDS IDENTIFICATION

<table>
<thead>
<tr>
<th>Product Name/Chemical Name</th>
<th>CAS Number</th>
<th>EC-No.</th>
<th>MW</th>
<th>Chemical Formula</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canertinib (CI-1033, PD-183805)</td>
<td>289499-45-2</td>
<td>--</td>
<td>558.86</td>
<td>C24H25ClFN5O3·2HCl</td>
</tr>
</tbody>
</table>

Canertinib (CI-1033, PD-183805):

Emergency Overview
OSHA Hazards: Irritant
GHS Classification:

- Skin irritation (Category 2)
- Eye irritation (Category 2A)
- Specific target organ toxicity – single exposure (Category 3)

GHS Label elements, including precautionary statements

Pictogram:

Signal word: Warning
Hazard statement(s):
- H315 Causes skin irritation.
- H319 Causes serious eye irritation.
- H335 May cause respiratory irritation.
Precautionary statement(s):
- P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
- P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

HMIS Classification

- Health hazard: 2
- Flammability: 0
- Physical hazards: 0

NFPA Rating

- Health Hazard: 2
- Fire: 0
- Reactivity Hazard: 0

Potential Health Effects

- Inhalation: May be harmful if inhaled. Causes respiratory tract irritation.
- Skin: May be harmful if absorbed through skin. Causes skin irritation.
- Eyes: Causes eye irritation.
- Ingestion: May be harmful if swallowed.

SECTION 4: FIRST AID MEASURES

General advice: Consult a physician. Show this safety data sheet to the doctor in attendance. Move out of dangerous area.
If inhaled: If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact: Wash off with soap and plenty of water. Consult a physician.
In case of eye contact: Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed: Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
SAFETY DATA SHEET
Cat# 1617-5, -50, Canertinib (CI-1033, PD-183805)  SDS DATE: Feb 29, 2012

5: FIRE-FIGHTING MEASURES

Condition of flammability: Not flammable or combustible.
Suitable extinguishing media: Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for fire-fighters: Wear self-contained breathing apparatus for firefighting if necessary.
Hazardous combustion products: Hazardous decomposition products formed under fire conditions— carbon oxides, nitrogen oxides, hydrogen chloride gas, hydrogen fluoride.

SECTION 6: ACCIDENTAL RELEASE MEASURES

Personal precautions: Use personal protection equipment. Avoid dust formation. Avoid breathing vapors, mist, gas, or dust. Ensure adequate ventilation. Evacuate personnel to safe areas.
Environmental precautions: Do not let product enter drains.
Methods for cleaning up: Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

SECTION 7: HANDLING AND STORAGE

Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection.
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: -20 °C

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

Contains no substances with occupational exposure limit values.
Personal protective equipment
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator. For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove’s outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
Eye protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin and body protection
Impervious clothing. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.
Hygiene measures
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of the workday.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Canertinib (CI-1033, PD-183805)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance:</td>
<td>Off-white to pale green solid</td>
</tr>
<tr>
<td>pH:</td>
<td>No data available</td>
</tr>
<tr>
<td>Water Solubility:</td>
<td>No data available</td>
</tr>
<tr>
<td>Other Solubility:</td>
<td>DMSO (100 mg/ml)</td>
</tr>
<tr>
<td>Specific Gravity (g/ml):</td>
<td>No data available</td>
</tr>
<tr>
<td>Boiling Point (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting Point (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash Point (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Ignition Temperature (°C):</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
</tbody>
</table>

SECTION 10: STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Property</th>
<th>Canertinib (CI-1033, PD-183805)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical stability:</td>
<td>Stable under recommended storage conditions</td>
</tr>
<tr>
<td>Conditions to avoid:</td>
<td>No data available</td>
</tr>
<tr>
<td>Materials to avoid:</td>
<td>Strong oxidizing agents</td>
</tr>
<tr>
<td>Hazardous decomposition products:</td>
<td>Carbon oxides, nitrogen oxides, hydrogen chloride gas, hydrogen fluoride</td>
</tr>
</tbody>
</table>
SECTION 11: TOXICOLOGICAL INFORMATION

Canertinib (CI-1033, PD-183805):
Acute toxicity: no data available
Skin corrosion/irritation: no data available
Serious eye damage/eye irritation: no data available
Respiratory or skin sensitization: no data available
Germ cell mutagenicity: no data available
Carcinogenicity:
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.
Reproductive toxicity: no data available
Teratogenicity: no data available
Specific target organ toxicity – single exposure (GHS): Inhalation – may cause respiratory irritation.
Specific target organ toxicity – repeated exposure (GHS): no data available
Aspiration hazard: no data available
Potential Health Effects
Inhalation: May be harmful if inhaled. Causes respiratory tract irritation.
Skin: May be harmful if absorbed through skin. Causes skin irritation.
Eyes: Causes eye irritation.
Ingestion: May be harmful if swallowed.
Signs and Symptoms of Exposure: To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Synergistic effects: no data available
Additional information: RTECS: UC6316110

SECTION 12: ECOLOGICAL INFORMATION

Canertinib (CI-1033, PD-183805):
Persistence and degradability: no data available
Toxicity: no data available
Bioaccumulative potential: no data available
Mobility in soil: no data available
PBT and vPvB assessment: no data available
Other adverse effects: no data available

SECTION 13: DISPOSAL CONSIDERATIONS

Product: Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste disposal service to dispose of this material.
Contaminated packaging: Dispose of as unused product.

SECTION 14: TRANSPORT INFORMATION

Canertinib (CI-1033, PD-183805):
DOT (US): Not dangerous goods.
IMDG: Not dangerous goods.
IATA: Not dangerous goods.

SECTION 15: REGULATORY INFORMATION

Canertinib (CI-1033, PD-183805):
OSHA Hazards: Irritant
DSL Status: This product contains the following components that are not on the Canadian DSL nor NDSL lists:
N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride, CAS-No. 289499-45-2
SARA 302 Components: SARA 302: No chemical in this material are subject to the reporting requirements of SARA Title II, Section 302.
SARA 313 Components: SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimus) reporting levels established by SARA Title II, Section 313.
SARA 311/312 Hazards: Acute Health Hazard
Massachusetts Right To Know Components: No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components: N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride, CAS-No. 289499-45-2
New Jersey Right To Know Components: N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride, CAS-No. 289499-45-2
California Prop. 65 Components: This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

### EU regulations

<table>
<thead>
<tr>
<th>Component</th>
<th>Risk Phrases</th>
<th>Safety Phrases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canertinib (CI-1033, PD-183805)</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>

### SECTION 16: OTHER INFORMATION

OTHER INFORMATION:
PREPARATION INFORMATION:

DISCLAIMER:
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. BioVision, Inc., shall not be held liable for any damage resulting from handling or from contact with the above product. See reverse side of invoice or packing slip for additional terms and conditions of sale.